Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $42.00 at HC Wainwright

Denali Therapeutics (NASDAQ:DNLI) had its target price hoisted by HC Wainwright from $32.00 to $42.00 in a report issued on Thursday morning, MarketBeat Ratings reports. HC Wainwright currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the company. BTIG Research increased their price target on Denali Therapeutics from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Robert W. Baird boosted their price objective on shares of Denali Therapeutics from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. UBS Group started coverage on shares of Denali Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating for the company. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $40.00 target price on shares of Denali Therapeutics in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.82.

Denali Therapeutics Stock Down 12.1%

DNLI opened at $19.74 on Thursday. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $23.77. The business has a 50 day moving average price of $20.43 and a two-hundred day moving average price of $17.81. The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01. The company has a market cap of $3.13 billion, a PE ratio of -6.65 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.02. During the same period in the previous year, the company earned ($0.67) earnings per share. As a group, research analysts anticipate that Denali Therapeutics will post -2.71 EPS for the current year.

Insider Buying and Selling at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 35,198 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the sale, the chief executive officer directly owned 296,833 shares in the company, valued at approximately $4,897,744.50. The trade was a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the sale, the insider directly owned 282,828 shares in the company, valued at $4,666,662. This trade represents a 5.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Headlands Technologies LLC purchased a new position in Denali Therapeutics during the 2nd quarter valued at about $26,000. Johnson Financial Group Inc. acquired a new position in Denali Therapeutics during the third quarter worth about $29,000. State of Wyoming purchased a new stake in shares of Denali Therapeutics in the second quarter valued at about $29,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Denali Therapeutics in the fourth quarter valued at approximately $57,000. Finally, Quarry LP acquired a new stake in shares of Denali Therapeutics in the third quarter valued at approximately $64,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA accelerated approval of AVLAYAH (tividenofusp alfa‑eknm), Denali’s first commercial drug and the first transferrin‑receptor (brain‑penetrant) biologic for Hunter syndrome; approval includes a Rare Pediatric Disease PRV and Denali is launching U.S. commercialization and patient support services. GlobeNewswire: DNLI FDA Approval Zacks: Denali Wins FDA Nod
• Positive Sentiment: Multiple brokerages boosted price targets and ratings today (Morgan Stanley to $42/overweight; Goldman Sachs to $40/buy; Stifel to $41/buy; BTIG, HC Wainwright, Baird also raised targets), signaling strong analyst conviction about AVLAYAH’s commercial and platform upside. Benzinga: Analyst Coverage Roundup
• Neutral Sentiment: Management hosted/announced a conference call and webcast to discuss approval and launch plans; an investor webcast and Seeking Alpha transcript provide additional color on commercialization timing, pricing strategy and the COMPASS confirmatory trial. Seeking Alpha: AVLAYAH Launch Transcript
• Negative Sentiment: The FDA approval is accelerated and based on a biomarker (CSF heparan sulfate); continued approval may be contingent on confirmatory Phase 2/3 COMPASS trial results — this creates execution and regulatory risk that could weigh on the stock if confirmatory data are delayed or mixed. GlobeNewswire: Approval Details & Risks
• Negative Sentiment: Reports show recent insider sales and significant institutional portfolio moves (large reductions by some funds reported), which can create near‑term supply pressure and headline risk despite the approval. QuiverQuant: Insider & Institutional Activity

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.